Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SENIOR: Toujeo vs Lantus in Older T2DM
NCT02320721Phase 3Completed
- Sponsor
- Sanofi
- Start
- Jan 2015
- Primary completion
- May 2016
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 18
01
Overview
Phase 3, randomised, open-label trial of insulin glargine in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Sanofi. Primary endpoint: Change in Glycated Hemoglobin A1c at 26 weeks. Started Jan 2015; status: completed.
02
Drugs
insulin glargine
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02320721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02320721.